Comparative Pharmacology
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus SYPRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus SYPRINE.
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs SYPRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromodiphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms. Codeine phosphate is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects. Combination provides enhanced cough suppression.
Syprine (trientine hydrochloride) is a chelating agent that forms stable complexes with copper, thereby increasing urinary excretion of copper and reducing pathological copper accumulation in tissues.
5 mL of oral solution (containing bromodiphenhydramine hydrochloride 12.5 mg and codeine phosphate 10 mg) every 4-6 hours as needed; maximum 4 doses in 24 hours.
250 mg to 500 mg orally 4 times daily, maximum 2000 mg daily.
None Documented
None Documented
Codeine: 2.5-3.5 h (adults), prolonged in hepatic impairment. Diphenhydramine: 4-8 h (adults), extended in elderly.
Approximately 48 hours in healthy subjects, reflecting prolonged accumulation with regular dosing, requiring careful monitoring for toxicity.
Renal: 70-80% as metabolites (codeine ~10% unchanged; diphenhydramine <5% unchanged). Biliary/fecal: 20-30%.
Primarily renal (approximately 50% unchanged within 24 hours after oral administration); biliary/fecal elimination accounts for a minor fraction (less than 10%).
Category A/B
Category C
Antihistamine
Antihistamine